Imugene (ASX:IMU) Investments And Advances : A$0.22 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Imugene Investments And Advances?

Imugene's Investments And Advances for the quarter that ended in Dec. 2023 was A$0.22 Mil.

Imugene's quarterly Investments And Advances increased from Dec. 2022 (A$0.22 Mil) to Jun. 2023 (A$0.22 Mil) but then stayed the same from Jun. 2023 (A$0.22 Mil) to Dec. 2023 (A$0.22 Mil).

Imugene's annual Investments And Advances increased from Jun. 2021 (A$0.12 Mil) to Jun. 2022 (A$0.25 Mil) but then declined from Jun. 2022 (A$0.25 Mil) to Jun. 2023 (A$0.22 Mil).

Imugene Investments And Advances Historical Data

The historical data trend for Imugene's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Investments And Advances Chart

Imugene Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Investments And Advances

Get a 7-Day Free Trial

0.05

0.08

0.12

0.25

0.22

Imugene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Investments And Advances	Get a 7-Day Free Trial															0.12	0.25	0.22	0.22	0.22

Imugene Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Imugene (ASX:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

IUGNF:USA

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines